Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
BioAtla Announces Share Consolidation
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
BioAtla, Inc. (NASDAQ:BCAB) Sees Large Drop in Short Interest
Brokerages Set BioAtla, Inc. (NASDAQ:BCAB) Target Price at $4.00
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest
Mirum Pharmaceuticals (NASDAQ:MIRM) & BioAtla (NASDAQ:BCAB) Financial Comparison
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
BioAtla Announces Regulatory Update on Clinical Development Plan for Ozuriftamab Vedotin in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Following Productive Type B (End of Phase 2) Meeting with FDA
BioAtla, Inc. (BCAB) Q2 2025 Earnings Call Transcript
BioAtla Reports Second Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting
BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
BioAtla, Inc. (BCAB) Q1 2025 Earnings Call Transcript
BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress
BioAtla to Participate in the Citizens Life Sciences Conference
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript
BioAtla Cuts 30% of Jobs in Restructuring Effort
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
AXL Inhibitors Pipeline Research Report 2025: Features Insights on 16+ Companies and 20+ Pipeline Drugs, Including Cabozantinib (Exelixis/Ipsen), BA 3011 (BioAtla) & TP-0903 (Sumitomo Dainippon Pharma Oncology)
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
BioAtla, Inc. (BCAB) Q3 2024 Earnings Call Transcript
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy
BioAtla: Numerous Catalysts Coming In Q4
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting
Michael Burry buys 634,000 shares of this $1 penny stock
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody